A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE) by Machiels, JP, Salazar, R, Rottey, S, Duran, I, Dirix, L, Geboes, K, Wilkinson-Blanc, C, Pover, G, Alvis, S, Champion, B, Fisher, K, McElwaine-Johnn, H, Beadle, J, Calvo, E